Literature DB >> 24713005

The present and future disease burden of hepatitis C virus (HCV) infection with today's treatment paradigm.

H Razavi1, I Waked, C Sarrazin, R P Myers, R Idilman, F Calinas, W Vogel, M C Mendes Correa, C Hézode, P Lázaro, U Akarca, S Aleman, I Balık, T Berg, F Bihl, M Bilodeau, A J Blasco, C E Brandão Mello, P Bruggmann, M Buti, J L Calleja, H Cheinquer, P B Christensen, M Clausen, H S M Coelho, M E Cramp, G J Dore, W Doss, A S Duberg, M H El-Sayed, G Ergör, G Esmat, K Falconer, J Félix, M L G Ferraz, P R Ferreira, S Frankova, J García-Samaniego, J Gerstoft, J A Giria, F L Gonçales, E Gower, M Gschwantler, M Guimarães Pessôa, S J Hindman, H Hofer, P Husa, M Kåberg, K D E Kaita, A Kautz, S Kaymakoglu, M Krajden, H Krarup, W Laleman, D Lavanchy, R T Marinho, P Marotta, S Mauss, C Moreno, K Murphy, F Negro, V Nemecek, N Örmeci, A L H Øvrehus, J Parkes, K Pasini, K M Peltekian, A Ramji, N Reis, S K Roberts, W M Rosenberg, F Roudot-Thoraval, S D Ryder, R Sarmento-Castro, D Semela, M Sherman, G E Shiha, W Sievert, J Sperl, P Stärkel, R E Stauber, A J Thompson, P Urbanek, P Van Damme, I van Thiel, H Van Vlierberghe, D Vandijck, H Wedemeyer, N Weis, J Wiegand, A Yosry, A Zekry, M Cornberg, B Müllhaupt, C Estes.   

Abstract

The disease burden of hepatitis C virus (HCV) is expected to increase as the infected population ages. A modelling approach was used to estimate the total number of viremic infections, diagnosed, treated and new infections in 2013. In addition, the model was used to estimate the change in the total number of HCV infections, the disease progression and mortality in 2013-2030. Finally, expert panel consensus was used to capture current treatment practices in each country. Using today's treatment paradigm, the total number of HCV infections is projected to decline or remain flat in all countries studied. However, in the same time period, the number of individuals with late-stage liver disease is projected to increase. This study concluded that the current treatment rate and efficacy are not sufficient to manage the disease burden of HCV. Thus, alternative strategies are required to keep the number of HCV individuals with advanced liver disease and liver-related deaths from increasing.
© 2014 John Wiley & Sons Ltd.

Entities:  

Keywords:  HCV; diagnosis; disease burden; epidemiology; hepatitis C; incidence; mortality; prevalence; treatment

Mesh:

Substances:

Year:  2014        PMID: 24713005     DOI: 10.1111/jvh.12248

Source DB:  PubMed          Journal:  J Viral Hepat        ISSN: 1352-0504            Impact factor:   3.728


  117 in total

1.  Hepatitis C Virus NS3/4A Protease Inhibitors Incorporating Flexible P2 Quinoxalines Target Drug Resistant Viral Variants.

Authors:  Ashley N Matthew; Jacqueto Zephyr; Caitlin J Hill; Muhammad Jahangir; Alicia Newton; Christos J Petropoulos; Wei Huang; Nese Kurt-Yilmaz; Celia A Schiffer; Akbar Ali
Journal:  J Med Chem       Date:  2017-06-19       Impact factor: 7.446

2.  Real-life cost of managing chronic HCV infection in Greece prior to Direct-Acting Antivirals (DAAs): an undeniable truth of spending more for less.

Authors:  K Souliotis; S Siakavellas; C Golna; E Manesis; G Papatheodoridis; A Hatzakis
Journal:  Hippokratia       Date:  2018 Jul-Sep       Impact factor: 0.471

Review 3.  Global epidemiology and burden of HCV infection and HCV-related disease.

Authors:  Aaron P Thrift; Hashem B El-Serag; Fasiha Kanwal
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2016-12-07       Impact factor: 46.802

Review 4.  Injecting drug use: A vector for the introduction of new hepatitis C virus genotypes.

Authors:  Simona Ruta; Costin Cernescu
Journal:  World J Gastroenterol       Date:  2015-10-14       Impact factor: 5.742

5.  Chronic hepatitis C virus (HCV) burden in Rhode Island: modelling treatment scale-up and elimination.

Authors:  A I Soipe; H Razavi; D Razavi-Shearer; O Galárraga; L E Taylor; B D L Marshall
Journal:  Epidemiol Infect       Date:  2016-08-05       Impact factor: 2.451

Review 6.  Potential Liver Transplant Recipients with Hepatitis C: Should They Be Treated Before or After Transplantation?

Authors:  Anil C Anand
Journal:  J Clin Exp Hepatol       Date:  2017-02-06

7.  Multicenter Evaluation of the Cepheid Xpert Hepatitis C Virus Viral Load Assay.

Authors:  M P McHugh; A H B Wu; S Chevaliez; J M Pawlotsky; M Hallin; K E Templeton
Journal:  J Clin Microbiol       Date:  2017-03-08       Impact factor: 5.948

8.  The full-length genome sequences of nine HCV genotype 4 variants representing a new subtype 4s and eight unclassified lineages.

Authors:  Ling Lu; Yan Xu; Jie Yuan; Chunhua Li; Donald G Murphy
Journal:  Virology       Date:  2015-04-05       Impact factor: 3.616

9.  Historical Trends in the Hepatitis C Virus Epidemics in North America and Australia.

Authors:  Chaturaka Rodrigo; Auda A Eltahla; Rowena A Bull; Jason Grebely; Gregory J Dore; Tanya Applegate; Kimberly Page; Julie Bruneau; Meghan D Morris; Andrea L Cox; William Osburn; Arthur Y Kim; Janke Schinkel; Naglaa H Shoukry; Georg M Lauer; Lisa Maher; Margaret Hellard; Maria Prins; Chris Estes; Homie Razavi; Andrew R Lloyd; Fabio Luciani
Journal:  J Infect Dis       Date:  2016-08-28       Impact factor: 5.226

10.  Projections of primary liver cancer to 2030 in 30 countries worldwide.

Authors:  Patricia C Valery; Mathieu Laversanne; Paul J Clark; Jessica L Petrick; Katherine A McGlynn; Freddie Bray
Journal:  Hepatology       Date:  2017-12-23       Impact factor: 17.425

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.